

Ole Isacson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1481281/ole-isacson-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

2,284
citations

21
h-index

47
g-index

53
ext. papers

2,630
ext. citations

11.9
avg, IF

4.81
L-index

#	Paper	IF	Citations
33	Glycosphingolipid metabolism and its role in ageing and Parkinson's disease. <i>Glycoconjugate Journal</i> , 2021 , 1	3	2
32	Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. <i>Molecular Brain</i> , 2021 , 14, 16	4.5	5
31	Cell type-specific lipid storage changes in Parkinson's disease patient brains are recapitulated by experimental glycolipid disturbance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 27646-27654	11.5	17
30	Upregulating Hexosaminidase activity in rodents prevents β -synuclein lipid associations and protects dopaminergic neurons from β -synuclein-mediated neurotoxicity. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 127	7.3	6
29	The Consequences of Coronavirus-Induced Cytokine Storm Are Associated With Neurological Diseases, Which May Be Preventable. <i>Frontiers in Neurology</i> , 2020 , 11, 745	4.1	4
28	Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 21, 623-635	10.7	18
27	Comprehensive Cell Surface Antigen Analysis Identifies Transferrin Receptor Protein-1 (CD71) as a Negative Selection Marker for Human Neuronal Cells. <i>Stem Cells</i> , 2019 , 37, 1293-1306	5.8	2
26	Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2019 , 14, 40	19	56
25	Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. <i>Neurobiology of Aging</i> , 2018 , 67, 189-200	5.6	50
24	The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. <i>Neurobiology of Disease</i> , 2018 , 120, 1-11	7.5	39
23	Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. <i>Molecular Neurobiology</i> , 2017 , 54, 2878-2888	6.2	16
22	Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. <i>Journal of Comparative Neurology</i> , 2017 , 525, 498-512	3.4	6
21	The Threshold Theory for Parkinson's Disease. <i>Trends in Neurosciences</i> , 2017 , 40, 4-14	13.3	111
20	hVMAT2: A Target of Individualized Medication for Parkinson's Disease. <i>Neurotherapeutics</i> , 2016 , 13, 623-34	6.4	8
19	Sustained Systemic Glucocerebrosidase Inhibition Induces Brain β -Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. <i>Antioxidants and Redox Signaling</i> , 2015 , 23, 550-64	8.4	79
18	Glucocerebrosidase gene therapy prevents β -synucleinopathy of midbrain dopamine neurons. <i>Neurobiology of Disease</i> , 2015 , 82, 495-503	7.5	88
17	Progressive decline of glucocerebrosidase in aging and Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 433-8	5.3	122

16	Lysosomes to combat Parkinson's disease. <i>Nature Neuroscience</i> , 2015 , 18, 792-3	25.5	6
15	Enhanced ubiquitin-dependent degradation by Nedd4 protects against β -synuclein accumulation and toxicity in animal models of Parkinson's disease. <i>Neurobiology of Disease</i> , 2014 , 64, 79-87	7.5	46
14	ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. <i>Experimental Neurology</i> , 2014 , 261, 217-29	5.7	9
13	Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. <i>Neurobiology of Disease</i> , 2008 , 30, 430-438	7.5	50
12	Ole Isacson: development of new therapies for Parkinson's disease (interview). <i>Journal of Visualized Experiments</i> , 2007 , 189	1.6	1
11	The production and use of cells as therapeutic agents in neurodegenerative diseases. <i>Lancet Neurology</i> , 2003 , 2, 417-24	24.1	88
10	Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. <i>Trends in Neurosciences</i> , 2002 , 25, 79-84	13.3	153
9	A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. <i>Human Gene Therapy</i> , 2001 , 12, 1731-40	4.8	122
8	Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. <i>Nature Medicine</i> , 1997 , 3, 350-3	50.5	406
7	Neuronal xenotransplantation in Parkinson's disease. <i>Nature Medicine</i> , 1997 , 3, 474-5	50.5	11
6	Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. <i>Magnetic Resonance in Medicine</i> , 1997 , 38, 389-98	4.4	216
5	Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. <i>Nature Medicine</i> , 1995 , 1, 1189-94	50.5	209
4	Article Commentary: Development of the Human Striatum: Implications for Fetal Striatal Transplantation in the Treatment of Huntington's Disease. <i>Cell Transplantation</i> , 1995 , 4, 539-545	4	33
3	Behavioral effects and gene delivery in a rat model of Parkinson's disease. <i>Science</i> , 1995 , 269, 856-7	33.3	36
2	A primate model of Huntington's disease: functional neural transplantation and CT-guided stereotactic procedures. <i>Cell Transplantation</i> , 1992 , 1, 313-22	4	30
1	Part B: Directed Differentiation of Human Embryonic Stem Cells into Dopaminergic Neurons 337-347		2